EMA Authorised: Piasky (Crovalimab) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency authorised Piasky (crovalimab) by Roche Registration GmbH for the treatment of paroxysmal nocturnal hemoglobinuria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• PIASKY (crovalimab)

Snippet

Status: Authorised. Therapeutic area: Hemoglobinuria, Paroxysmal. MAH: Roche Registration GmbH. Decision date: 17/10/2025